Current Treatment Options in Gastroenterology

, Volume 8, Issue 1, pp 19–30

Medical therapy of Crohn’s disease

  • Shamina Dhillon
  • Edward V. LoftusJr
Article

Opinion statement

There is no medical or surgical treatment that provides a permanent cure for Crohn’s disease (CD). However, an evolving understanding of the pathogenesis of CD has provided clinicians with a diversity of medical treatment options for the disease. The goal of therapy is to induce and maintain clinical remission. The efficacy of immune-modifying agents such as azathioprine/6-mercaptopurine and infliximab have supported a paradigm shift in CD treatment in which maintenance agents are introduced earlier in the disease course. At the same time, it is imperative to balance the efficacy, safety, and tolerability of medical therapy. Given the variable and relapsing clinical course of CD, the physician and patient should ideally develop an ongoing relationship that allows for individualization of treatment regimens, monitoring of response and side effects, and modification of the therapeutic strategy in the absence of improvement.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Loftus EV Jr: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126: 1504–1517.PubMedCrossRefGoogle Scholar
  2. 2.
    Farmer RG, Hawk WA, Turnbull RB, Jr: Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology 1975, 68: 627–635.PubMedGoogle Scholar
  3. 3.
    Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6: 8–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Cosnes J, Cattan S, Blain A, et al.: Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002, 8: 244–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Sands BE: Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999, 28: 323–351.PubMedCrossRefGoogle Scholar
  6. 6.
    Hanauer SB, Sandborn W: Practice Parameters Committee of the American College of G. Management of Crohn’s disease in adults. Am J Gastroenterol 2001, 96: 635–643. Most recent practice guidelines for CD in adults from the American College of Gastroenterology.PubMedCrossRefGoogle Scholar
  7. 7.
    Cosnes J, Carbonnel F, Beaugerie L, et al.: Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 1996, 110: 424–431.PubMedCrossRefGoogle Scholar
  8. 8.
    Cosnes J, Beaugerie L, Carbonnel F, et al.: Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001, 120: 1093–1099.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandborn WJ, Feagan BG: Review article: mild to moderate Crohn’s disease—defining the basis for a new treatment algorithm. Aliment Pharmaco Ther 2003, 18: 263–277.CrossRefGoogle Scholar
  10. 10.
    Harrell LE, Hanauer SB: Mesalamine derivatives in the treatment of Crohn’s disease. Gastroenterol Clin North Am 2004, 33: 303–317.PubMedCrossRefGoogle Scholar
  11. 11.
    Summers RW, Switz DM, Sessions JT, Jr, et al.: National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979, 77: 847–869.PubMedGoogle Scholar
  12. 12.
    Prantera C, Cottone M, Pallone F, et al.: Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology 1999, 116: 521–526.PubMedCrossRefGoogle Scholar
  13. 13.
    Singleton JW, Hanauer SB, Gitnick GL, et al.: Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. Gastroenterology 1993, 104: 1293–1301.PubMedGoogle Scholar
  14. 14.
    Tremaine WJ, Schroeder KW, Harrison JM, et al.: A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol 1994, 19: 278–282.PubMedCrossRefGoogle Scholar
  15. 15.
    Hanauer SB, Stromberg U: Oral Pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004, 2: 379–388.PubMedCrossRefGoogle Scholar
  16. 16.
    Malchow H, Ewe K, Brandes JW, et al.: European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984, 86: 249–266.PubMedGoogle Scholar
  17. 17.
    Camma C, Giunta M, Rosselli M, et al.: Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113: 1465–1473. Meta-analysis of mesalamine for maintenance of remission in Crohn’s disease, suggesting minimal if any efficacy for medically induced remission, and low to moderate efficacy for surgically induced remission.PubMedCrossRefGoogle Scholar
  18. 18.
    Lochs H, Mayer M, Fleig WE, et al.: Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000, 118: 264–273.PubMedCrossRefGoogle Scholar
  19. 19.
    Sutherland L, Singleton J, Sessions J, et al.: Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991, 32: 1071–1075.PubMedGoogle Scholar
  20. 20.
    Arnold GL, Beaves MR, Pryjdun VO, et al.: Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 2002, 8: 10–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Colombel JF, Lemann M, Cassagnou M, et al.: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999, 94: 674–678.PubMedCrossRefGoogle Scholar
  22. 22.
    Brandt LJ, Bernstein LH, Boley SJ, et al.: Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982, 83: 383–387.PubMedGoogle Scholar
  23. 23.
    Schleimer RP: Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990, 141: S59-S69.PubMedGoogle Scholar
  24. 24.
    Katz JA: Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am 2004, 33: 171–189.PubMedCrossRefGoogle Scholar
  25. 25.
    Baker DE: Budesonide modified-release capsules. Rev Gastroenterol Dis 2001, 1: 147–155.Google Scholar
  26. 26.
    Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331: 836–841.PubMedCrossRefGoogle Scholar
  27. 27.
    Kane SV, Schoenfeld P, Sandborn WJ, et al.: The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmaco Thera 2002, 16: 1509–1517. Meta-analysis of all trials of budesonide for both active Crohn’s disease and maintenance of remission.CrossRefGoogle Scholar
  28. 28.
    Thomsen OO, Cortot A, Jewell D, et al.: A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998, 339: 370–374.PubMedCrossRefGoogle Scholar
  29. 29.
    Bar-Meir S, Chowers Y, Lavy A, et al.: Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 1998, 115: 835–840.PubMedCrossRefGoogle Scholar
  30. 30.
    Campieri M, Ferguson A, Doe W, et al.: Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997, 41: 209–214.PubMedCrossRefGoogle Scholar
  31. 31.
    Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43: 329–339.PubMedCrossRefGoogle Scholar
  32. 32.
    Markowitz JF: Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn’s disease. Rev Gastroenterol Dis 2003, 3: S23-S29.Google Scholar
  33. 33.
    Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980, 302: 981–987.PubMedCrossRefGoogle Scholar
  34. 34.
    Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995, 37: 674–8.PubMedGoogle Scholar
  35. 35.
    Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000, 2: CD000545.PubMedGoogle Scholar
  36. 36.
    Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985, 30: 58–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Pearson DC, May GR, Fick G, et al.: Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000, 2: CD000067.PubMedGoogle Scholar
  38. 38.
    Willoughby JM, Beckett J, Kumar PJ, et al.: Controlled trial of azathioprine in Crohn’s disease. Lancet 1971, 2: 944–947.PubMedCrossRefGoogle Scholar
  39. 39.
    Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119: 895–902.PubMedCrossRefGoogle Scholar
  40. 40.
    Hanauer S: Postoperative Maintenance of Crohn’s Disease Remission With 6-Mercaptopurine, Mesalamine, or Placebo: A 2-Year Trial. Gastroenterology 2004, 127: 723–729. This trial showed that 6-MP 50 mg daily, but not mesalamine, was more effective than placebo at preventing postoperative recurrence in CD.PubMedCrossRefGoogle Scholar
  41. 41.
    Ardizzane S, Marconi G, Sampietro GM, et al.: Azathioprine and mesalmine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004, 127: 730–740.CrossRefGoogle Scholar
  42. 42.
    Sandborn WJ: Pharmacogenomics and IBD: TPMT and thiopurines. Inflamm Bowel Dis 2004, 10: S35–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Korelitz BI, Mirsky FJ, Fleisher MR, et al.: Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94: 3248–3253.PubMedCrossRefGoogle Scholar
  44. 44.
    Connell WR, Kamm MA, Dickson M, et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343: 1249–1252.PubMedCrossRefGoogle Scholar
  45. 45.
    Kandiel AE, Korelitz BI, et al.: Azathioprine and 6-Mercaptopurine Use for Inflammatory Bowel Disease is Associated with and Increased Risk of Lymphoma. Gastroenterology 2004, 126: A-19.Google Scholar
  46. 46.
    Egan LJ, Sandborn WJ: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996, 71: 69–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91: 423–433.PubMedGoogle Scholar
  48. 48.
    Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342: 1627–1632. This trial showed that a low dose of MTX maintained remission in those patients who successfully entered remission with MTX treatment of 25 mg IM.PubMedCrossRefGoogle Scholar
  49. 49.
    Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995, 332: 292–297.PubMedCrossRefGoogle Scholar
  50. 50.
    Arora S, Katkov W, Cooley J, et al.: Methotrexate in Crohn’s disease: results of a randomized, doubleblind, placebo-controlled trial. Hepato Gastroenterology 1999, 46: 1724–1729.PubMedGoogle Scholar
  51. 51.
    Oren R, Moshkowitz M, Odes S, et al.: Methotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997, 92: 2203–2209.PubMedGoogle Scholar
  52. 52.
    Brynskov J, Freund L, Rasmussen SN, et al.: A placebocontrolled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989, 321: 845–850.PubMedCrossRefGoogle Scholar
  53. 53.
    Feagan BG, McDonald JW, Rochon J, et al.: Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med 1994, 330: 1846–1851.PubMedCrossRefGoogle Scholar
  54. 54.
    Stange EF, Modigliani R, Pena AS, et al.: European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. The European Study Group. Gastroenterology 1995, 109: 774–782.PubMedCrossRefGoogle Scholar
  55. 55.
    Flanagan WM, Corthesy B, Bram RJ, et al.: Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991, 352: 803–807.PubMedCrossRefGoogle Scholar
  56. 56.
    Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125: 380–388. This trial showed that oral tacrolimus at a dose of 0.2/mg/kg was effective for fistula improvement, though not for fistula remission, in patients with perianal Crohn’s disease.PubMedCrossRefGoogle Scholar
  57. 57.
    Loftus CG, Egan LJ, Sandborn WJ: Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004, 33: 141–69.PubMedCrossRefGoogle Scholar
  58. 58.
    Lipsky JJ: Mycophenolate mofetil. Lancet 1996, 348: 1357–1359.PubMedCrossRefGoogle Scholar
  59. 59.
    Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999, 44: 625–628.PubMedCrossRefGoogle Scholar
  60. 60.
    Valle E, Gross M, Bickston SJ: Infliximab. Expert Opin Pharmacother 2001, 2: 1015–1025.PubMedCrossRefGoogle Scholar
  61. 61.
    Ksontini R, MacKay SL, Moldawer LL: Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 1998, 133: 558–567.PubMedCrossRefGoogle Scholar
  62. 62.
    Scallon BJ, Moore MA, Trinh H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7: 251–259.PubMedCrossRefGoogle Scholar
  63. 63.
    Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol 2002, 97: 2962–2972.PubMedCrossRefGoogle Scholar
  64. 64.
    Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease.[ see comment]. N Engl J Med 2004, 350: 876–885. This trial showed that those patients with CD fistulas who had an initial response to induction therapy with infliximab had a higher likelihood of a sustained response if infliximab therapy is continued every 8 weeks.PubMedCrossRefGoogle Scholar
  65. 65.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359: 1541–1549. Large randomized controlled trial demonstrating the efficacy of infliximab in maintaining remission of inflammatory Crohn’s disease.PubMedCrossRefGoogle Scholar
  66. 66.
    Comerford LW, Bickston SJ: Treatment of luminal and fistulizing Crohn’s disease with infliximab. Gastroenterology Clinics of North America 2004, 33: 387–406.PubMedCrossRefGoogle Scholar
  67. 67.
    Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial.[see comment]. Gastroenterology 2003, 124: 917–924.PubMedCrossRefGoogle Scholar
  68. 68.
    Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001, 345: 1098–1104.PubMedCrossRefGoogle Scholar
  69. 69.
    Bickston SJ, Lichtenstein GR, Arseneau KO, et al.: The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999, 117: 1433–1437.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Shamina Dhillon
    • 1
  • Edward V. LoftusJr
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations